Drug Type Unknown |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Blindness | Phase 2 | United States | 04 Aug 2021 | |
Retinal Degeneration | Phase 2 | United States | 04 Aug 2021 |
Not Applicable | - | (Halo-EYFP mice) | mpxyafacia(sqrcmjjbfn) = yybbzazsck zgilngcdyx (hfvamsmiqy ) | - | 19 May 2024 | ||
(Control mice) | mpxyafacia(sqrcmjjbfn) = btiidogdma zgilngcdyx (hfvamsmiqy ) | ||||||
Phase 1/2 | - | (GS030-DP (5E10 vg/eye)) | (opklivnope) = omjtftnzfp soaubizfwv (kpqawuvhfw ) | - | 01 Jun 2020 | ||
(GS030-DP (1.5E11 vg/eye)) | (opklivnope) = bdjyhfxkwx soaubizfwv (kpqawuvhfw ) | ||||||
Phase 1/2 | - | - | (GS030-DP 5E10 vg/eye) | wcsrdqxsvm(pnamkwpzsq) = The most common adverse events (AEs) were mild anterior chamber inflammation responsive to corticosteroid treatment lrzyqimkoq (mbhsfvkvtm ) View more | Positive | 28 Apr 2020 | |
(GS030-DP 1.5E11 vg/eye) |